Bispecific Antibodies (BsAbs) are antibodies that contain two different antigens or have two different epitopes on the same antigen. It is observed for Bispecific Antibodies in clinical trials that the therapeutic effects of these are considerably higher than those of monoclonal antibodies (MoAbs). There are a vast...
Find MoreNHS Grants Fast Track Access to Takeda’s Exkivity Takeda has secured UK approval for its lung cancer therapy Exkivity, with an NHS access deal that could see it prescribed to patients within the next few weeks. The Medicines and Healthcare products Regulatory Agency has granted conditional marketing authorisa...
Find MoreGSK’s Covifenz, A Plant-Based COVID Vaccine, Receives First Approval The recombinant COVID-19 vaccine developed by Medicago, now known as Covifenz, has received approval in Canada, the company's home country. Covifenz employs Coronavirus-Like Particle (CoVLP) technology, with the vaccine consisting of recombinan...
Find MoreBiogen's Aduhelm Marketing and Approval are Under Scrutiny in New FTC and SEC Investigations Biogen can't seem to get a break when it comes to the Alzheimer's disease drug Aduhelm. Along with limited sales and a constraining Medicare coverage plan, the medicine is now facing additional scrutiny as part of a pair...
Find MoreSuneva Medical Inc. inked a merger agreement with Viveon Health On January 12, 2022, Suneva Medical Inc., a leading regenerative aesthetics company, and Viveon Health Acquisition Corp., a particular purpose acquisition company, entered into a definitive merger agreement to establish a new regenerative aesthetics...
Find MoreBiogen-Eisai's potential Aduhelm sequel drug secured speedy review by FDA Biogen and Eisai’s Alzheimer’s disease treatment-in-waiting, lecanemab, has been secured a fast-track tag by the FDA, setting up a potentially swift path through the regulatory process. The drug is the next in line behind the pair’s app...
Find MoreAslan Pharmaceuticals enters into a strategic collaboration with IQVIA ASLAN Pharmaceuticals announced the appointment of IQVIA Biotech, a provider of analytics, technology solutions, and clinical research services to the life sciences industry, as its preferred clinical research organisation for log...
Find MoreAlzheimer’s disease (AD) is a progressive neurodegenerative disease that is a lead cause of dementia in approximately 5.8 million Americans. Further, it is estimated that the number will soar to 13.5 million by 2050. Owing to the R&D done in understanding Alzheimer’s disease so far, it has been clear t...
Find MoreValo Health receives USD 110 Million Series B from Koch Valo Health launched in September with USD 100 million and a couple of acquisitions under its belt to transform drug development and cut years off R&D timelines. Now, it is filling with USD 110 million from Koch Disruptive Technologies that will bolster...
Find MoreCNS disorders are a wide-ranging set of disorders in which the brain loses its normal functioning, limiting everyday ability to function. These may arise from various reasons-some are inherited, some result from damage, and some from infections. It contributes to the highest disability-adjusted life years. The curr...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.